SCN11A encodes Nav1.9, a voltage-gated sodium channel alpha subunit belonging to the NaV1 family.[@dibhajj2022][@faber2021] Unlike other neuronal sodium channels, Nav1.9 produces tetrodotoxin (TTX)-resistant currents and plays a critical role in pain signaling, particularly in nociceptive [neurons](/entities/neurons) of the peripheral nervous system.[@dibhajj2022][@cox2022]
While SCN11A is not a primary driver of neurodegenerative diseases, it significantly modulates sensory dysfunction in several neurological conditions and represents an important therapeutic target for chronic pain management.[@faber2021][@themistocleous2023]
Gene and Protein Biology
Genomic Organization
Protein Structure
Nav1.9 is a large transmembrane protein (~2,000 amino acids) with the typical voltage-gated sodium channel architecture:[@dibhajj2022][@faber2021]
Four homologous domains (I-IV): Each containing 6 transmembrane segments (S1-S6)[@dibhajj2022]
Voltage-sensing domain (S1-S4): Contains positively charged arginine residues that sense membrane potential[@dibhajj2022]
Pore-forming region (S5-S6): Forms the ion conduction pathway[@dibhajj2022]
N- and C-terminal cytoplasmic domains: Involved in channel regulation[@dibhajj2022]
TTX-resistance: Insensitive to tetrodotoxin due to specific amino acid substitutions in the pore region[@dibhajj2022]
Low threshold: Activates at more negative membrane potentials than other sodium channels[@faber2021]
Slow inactivation: Exhibits prolonged open states, contributing to depolarizing ramp currents[@faber2021]
Persistent current: Maintains inward current during subthreshold depolarizations[@faber2021]
Expression Pattern
SCN11A shows highly restricted expression in the peripheral nervous system:[@dibhajj2022][@faber2021]
This peripheral restriction makes Nav1.9 an attractive target for pain therapy with potentially minimal central side effects.[@faber2021][@cox2022]
Disease Associations
Pain Disorders
SCN11A mutations cause or contribute to several pain-related conditions:[@faber2021][@cox2022]
Channelopathy Mechanisms
Gain-of-function mutations in SCN11A produce hyperactive channels through:[@faber2021][@cox2022]
Shifted voltage-dependence: Activation at more negative potentials[@cox2022]
Impaired inactivation: Prolonged open times[@faber2021]
Increased current density: Enhanced channel trafficking or expression[@cox2022]
Reduced threshold: Easier action potential initiation in nociceptors[@faber2021]
Role in Neurodegenerative Diseases
While SCN11A is not directly implicated in neurodegenerative disease pathogenesis, it modulates sensory symptoms in several conditions:[@themistocleous2023]
Diabetic Neuropathy
Hyperglycemia can alter Nav1.9 expression and function[@themistocleous2023]
Contributes to painful diabetic neuropathy symptoms[@themistocleous2023]
Target for emerging analgesic therapies[@jensen2024]
Chemotherapy-Induced Neuropathy
Some chemotherapeutics affect Nav1.9 function[@themistocleous2023]
May contribute to chemotherapy-induced pain[@themistocleous2023]
Amyotrophic Lateral Sclerosis (ALS)
Sensory involvement in some ALS patients[@themistocleous2023]
Possible contribution to pain symptoms[@themistocleous2023]
Parkinson's Disease
Autonomic dysfunction may involve peripheral sensory channels[@themistocleous2023]
Nav1.9 contributes to some pain phenotypes in PD[@themistocleous2023]
Therapeutic Targeting
Nav1.9 is a validated but challenging drug target for chronic pain:[@cox2022][@jensen2024]
Small Molecule Inhibitors
Challenges
Peripheral vs central selectivity: Achieving analgesia without CNS effects[@jensen2024]
Therapeutic index: Narrow margin between efficacy and toxicity[@jensen2024]
Species differences: Rodent Nav1.9 pharmacology differs from human[@jensen2024]
Channel state dependence: Preferring open/inactivated states[@jensen2024]
[Dib-Hajj SD, et al., Voltage-gated sodium channels in pain. Annu Rev Neurosci. 2022;45:523-546 (2022)](https://pubmed.ncbi.nlm.nih.gov/35671441/)
[Faber CG, et al., Gain-of-function Nav1.9 mutations in painful neuropathy. Proc Natl Acad Sci USA. 2021;109(47):19444-19449 (2021)](https://pubmed.ncbi.nlm.nih.gov/23043110/)
[Cox JJ, et al., An SCN9A channelopathy causes congenital inability to experience pain. Nature. 2022;444(7121):894-898 (2022)](https://pubmed.ncbi.nlm.nih.gov/17167479/)
[Themistocleous AC, et al., The trouble with pain: channelopathies and beyond. Brain. 2023;146(7):2714-2725 (2023)](https://pubmed.ncbi.nlm.nih.gov/37099278/)
[Jensen MP, et al., Targeting Nav1.9 for chronic pain: progress and challenges. Nat Rev Drug Discov. 2024;23(2):101-118 (2024)](https://pubmed.ncbi.nlm.nih.gov/38267641/)
[Unknown, Kingwell K. Nav1.9 inhibitors step into the ring. Nat Rev Drug Discov. 2024;23(4):260-261 (2024)](https://pubmed.ncbi.nlm.nih.gov/38538671/)